Therefore, exosomes represent a novel source of tumor-rejection antigens for T-cell cross priming, relevant for immunointerventions.

Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res. 1997;3:2191-2196. Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN.

[1] In their report, the authors develop weighted criteria to prioritize tumor vaccine antigens with the goal of identifying rational criteria to move individual antigens forward in development ...

This can trigger extensive proliferation of CAR T cells and the release of tumor antigens, which activates the immune system to recruit non–CAR T cells, thus eliciting further antitumor ...

Using T cell receptor sequencing on both functionally expanded T cells and neoantigen-loaded tetramer-sorted T cells, we identified tumor antigen-specific T cell receptors,” write the investigators.

Tumor antigens and soluble tumor products attract ... make interleukin-4 and interleukin-13 and are not effective in tumor rejection. This immunosuppressive environment also promotes generation ...

but in some patients we may not know what the most effective tumor rejection antigen is,” says James L. Gulley, M.D., Ph.D., chief, genitourinary malignancies branch at the National Cancer ...

All of the cancer vaccines discussed here are therapeutic vaccines. They are designed to stimulate the patients' immune system to recognize and reject their own cancer after it has been diagnosed.